Drug Trial Radar · NCT07412613
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
386
Planned (sponsor's estimate)
Start
Apr 15, 2026
Primary completion
Jun 15, 2030
Study completion Mar 15, 2031
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant/adjuvant treatment of AK104 (Cadonilimab) versus adjuvant chemotherapy in patients with resectable MSI-H/dMMR colon cancer.
Conditions
- Resectable Colon Cancer
- MSI-H/dMMR Colorectal Cancer
Interventions
Cadonilimab (AK104)Drug
Anti-PD-1/CTLA-4 tetrameric bispecific antibody
OxaliplatinDrug
Intravenous
CapecitabineDrug
Oral
5- FluorouracilDrug
Intravenous
Calcium FolinateDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathologic Complete Response (pCR) rate as assessed by investigatorTime frame: 1 month after surgery
- Event Free Survival (EFS)Time frame: Up to approximately 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.